Selcia and Heptares Therapeutics Announce New Fragment Screening Collaboration
News Apr 19, 2012
Selcia Limited has announced that it has entered into a new collaboration with Heptares Therapeutics Limited to discover fragment ligands that specifically bind to a Family B stabilized GPCR (StaR®) drug target purified by Heptares.
This follows the successful conclusion of an initial proof-of-concept study using a Family A StaR®.
Selcia will initially develop a screening assay and then apply its novel CEfrag™ drug discovery technology to confirm hits already obtained by Heptares and to screen its proprietary fragment library against the Heptares target.
Selcia’s CEfrag™ platform utilizes capillary electrophoresis technology to identify fragment compounds that selectively bind to drug targets.
All reagents are in solution and no tethering of the protein is required, enabling near physiological ligand/target interactions to be observed with a low false positive rate.
As well as stabilized GPCRs, CEfrag™ can be used to detect fragment/target interactions across a wide range of other target classes including “challenging” targets such as protein-protein interactions.
“We are delighted that Heptares has selected Selcia to carry out the screening of this new GPCR drug target using Selcia’s CEfrag™ platform which has been made possible with Heptares’ StaR technology” said Simon Saxby, CEO of Selcia Limited.
Saxby continued, “We are looking forward to identifying novel fragment compounds against this new target and to continuing our collaboration with the scientists at Heptares.”
Dr Miles Congreve, Head of Chemistry at Heptares Therapeutics, commented, “As Selcia’s CEfrag™ fragment screening platform does not require tethering of the drug target this makes it a very powerful technology to screen drug targets like GPCRs and in particular to StaRs®. This screening technology could be a valuable additional tool as part of a comprehensive structure-based drug discovery capability. We therefore look forward to working with Selcia and building upon our already successful relationship.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE